Cormorant Asset Management’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

Cormorant Asset Management’s Portfolio YARW Stock Details YARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-27,419	Closed	-$2.26M	–	43
2025 Q2	$2.26M	Buy	+27,419	New	+$1.78M	0.17%	41
2025 Q1	–	Sell	-27,887	Closed	-$4.67M	–	50
2024 Q4	$4.67M	Hold	27,887	–	–	0.26%	38
2024 Q3	$2.62M	Hold	27,887	–	–	0.14%	42
2024 Q2	$2.75M	Hold	27,887	–	–	0.16%	46
2024 Q1	$4.28M	Hold	27,887	–	–	0.19%	56
2023 Q4	$3.25M	Buy	+27,887	New	+$4.35M	0.16%	46
2018 Q2	–	Sell	-94	Closed	-$12.7M	–	61
2018 Q1	$12.7M	Buy	+94	New	+$11.4M	0.94%	25

Other funds holding YARW

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Cormorant Asset Management's YARW Position: Q3 2025 in Review

Cormorant Asset Management sold out of Yarrow Bioscience, Inc. Common Stock (YARW) in Q3 2025, closing a stake of 27,419 shares — an estimated $2.26M sold.

Cormorant Asset Management first reported a position in YARW in Q1 2018 and held it in 7 quarters. The position peaked at $12.7M in Q1 2018. 34 funds tracked by Wall St. Rank hold YARW as of Q3 2025.

Cormorant Asset Management reported no remaining Yarrow Bioscience, Inc. Common Stock position as of Q3 2025 after selling out during the quarter.
Cormorant Asset Management sold 27,419 Yarrow Bioscience, Inc. Common Stock shares in Q3 2025, an estimated $2.26M.
Cormorant Asset Management first reported a position in Yarrow Bioscience, Inc. Common Stock in Q1 2018 and held it in 7 quarters.
Cormorant Asset Management's Yarrow Bioscience, Inc. Common Stock position peaked at $12.7M in Q1 2018.
34 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q3 2025.

Based on Cormorant Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.